Literature DB >> 8851721

DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese.

Y Date1, A Kimura, H Kato, T Sasazuki.   

Abstract

With the use of polymerase chain reaction (PCR) and sequence-specific oligonucleotide probe (SSOP), we established a DNA typing method of the HLA-A locus. A pair of primers to amplify the highly polymorphic region of HLA-A gene including exon 2 and exon 3 was designed and the amplified DNAs were hybridized with 91 types of 32P labeled SSOPs. This method allowed discrimination of all known HLA-A alleles except for two combinations, A*0201 or A*0209 and A*0207 or A*0215N, which have identical sequences in exon 2 and exon 3. Another pair of primers was designed for amplification of exon 4 and the PCR products were hybridized with 5 SSOPs to distinguish A*0201 and A*0207 from A*0209 and A*0215N, respectively. In this study, 81 B-lymphoblastoid cell lines (BLCL) homozygous for HLA and 553 unrelated healthy Japanese individuals were determined for their HLA-A genotypes. Based on the genotyping results, frequency of HLA-A alleles and linkage disequilibrium between HLA-A and HLA-B in the Japanese population were investigated. In addition, four new HLA-A alleles were identified and their nucleotide sequences in exon 2 and exon 3 were determined to confirm the typing results.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851721     DOI: 10.1111/j.1399-0039.1996.tb02520.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  16 in total

1.  Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigen.

Authors:  Venkataswarup Tiriveedhi; Nayan J Sarma; Vijay Subramanian; Timothy P Fleming; William E Gillanders; Thallachallour Mohanakumar
Journal:  Hum Immunol       Date:  2011-10-23       Impact factor: 2.850

2.  Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer.

Authors:  Hitomi Nagayama; Kazufumi Matsumoto; Naoyuki Isoo; Hideki Ohno; Naoyuki Takahashi; Takashi Nakaoka; Masaru Shinozaki; Makoto Watanabe; Yusuke Inoue; Fumitaka Nagamura; Naoki Oyaizu; Naohide Yamashita
Journal:  Clin J Gastroenterol       Date:  2010-09-25

Review 3.  Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.

Authors:  Toshiki Ochi; Hiroshi Fujiwara; Masaki Yasukawa
Journal:  J Biomed Biotechnol       Date:  2010-05-05

4.  Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.

Authors:  Toshiyuki Baba; Marimo Sato-Matsushita; Akira Kanamoto; Akihiko Itoh; Naoki Oyaizu; Yusuke Inoue; Yutaka Kawakami; Hideaki Tahara
Journal:  J Transl Med       Date:  2010-09-16       Impact factor: 5.531

5.  Tumor vaccines in renal cell carcinoma.

Authors:  Hirotsugu Uemura; Marco A De Velasco
Journal:  World J Urol       Date:  2008-03-12       Impact factor: 4.226

6.  Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice.

Authors:  Yuho Najima; Mariko Tomizawa-Murasawa; Yoriko Saito; Takashi Watanabe; Rintaro Ono; Toshiki Ochi; Nahoko Suzuki; Hiroshi Fujiwara; Osamu Ohara; Leonard D Shultz; Masaki Yasukawa; Fumihiko Ishikawa
Journal:  Blood       Date:  2015-12-23       Impact factor: 22.113

7.  Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.

Authors:  Koji Kono; Hisae Iinuma; Yasunori Akutsu; Hiroaki Tanaka; Naoko Hayashi; Yasuto Uchikado; Tsuyoshi Noguchi; Hideki Fujii; Kota Okinaka; Ryoji Fukushima; Hisahiro Matsubara; Masaichi Ohira; Hideo Baba; Shoji Natsugoe; Seigou Kitano; Kazuyoshi Takeda; Koji Yoshida; Takuya Tsunoda; Yusuke Nakamura
Journal:  J Transl Med       Date:  2012-07-09       Impact factor: 5.531

8.  A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes.

Authors:  S Shichijo; M Nakao; Y Imai; H Takasu; M Kawamoto; F Niiya; D Yang; Y Toh; H Yamana; K Itoh
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

9.  Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas.

Authors:  H Tanaka; T Tsunoda; I Nukaya; A Sette; K Matsuda; Y Umano; H Yamaue; K Takesako; H Tanimura
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

10.  Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.

Authors:  Ichiya Honma; Toshihiko Torigoe; Yoshihiko Hirohashi; Hiroshi Kitamura; Eiji Sato; Naoya Masumori; Yasuaki Tamura; Taiji Tsukamoto; Noriyuki Sato
Journal:  J Transl Med       Date:  2009-12-09       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.